Literature DB >> 28303515

Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease.

Valentina Guarnotta1, Alessandro Ciresi1, Maria Pitrone1, Giuseppe Pizzolanti1, Carla Giordano2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28303515     DOI： 10.1007/s12020-017-1276-7

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  19 in total

1.  The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.

Authors:  R van der Pas; C de Bruin; F W G Leebeek; M P M de Maat; D C Rijken; A M Pereira; J A Romijn; R T Netea-Maier; A R Hermus; P M J Zelissen; F H de Jong; A J van der Lely; W W de Herder; S W J Lamberts; L J Hofland; R A Feelders
Journal:  J Clin Endocrinol Metab       Date:  2012-01-25       Impact factor: 5.958

2.  Endoscopic transsphenoidal surgery for cushing disease: techniques, outcomes, and predictors of remission.

Authors:  Robert M Starke; Davis L Reames; Ching-Jen Chen; Edward R Laws; John A Jane
Journal:  Neurosurgery       Date:  2013-02       Impact factor: 4.654

Review 3.  Insulin resistance, small LDL particles, and risk for atherosclerotic disease.

Authors:  Peter P Toth
Journal:  Curr Vasc Pharmacol       Date:  2014       Impact factor: 2.719

4.  Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?

Authors:  Carla Giordano; Valentina Guarnotta; Rosario Pivonello; Marco Calogero Amato; Chiara Simeoli; Alessandro Ciresi; Alessia Cozzolino; Annamaria Colao
Journal:  Eur J Endocrinol       Date:  2013-12-21       Impact factor: 6.664

5.  The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome.

Authors:  Valentina Guarnotta; Marco C Amato; Rosario Pivonello; Giorgio Arnaldi; Alessandro Ciresi; Laura Trementino; Roberto Citarrella; Davide Iacuaniello; Grazia Michetti; Chiara Simeoli; Annamaria Colao; Carla Giordano
Journal:  Endocrine       Date:  2016-03-10       Impact factor: 3.633

6.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

7.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

8.  Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.

Authors:  Rosario Pivonello; Stephan Petersenn; John Newell-Price; James W Findling; Feng Gu; Mario Maldonado; Andrew Trovato; Gareth Hughes; Luiz R Salgado; André Lacroix; Jochen Schopohl; Beverly M K Biller
Journal:  Clin Endocrinol (Oxf)       Date:  2014-03-27       Impact factor: 3.478

9.  Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.

Authors:  Jochen Schopohl; Feng Gu; Robert Rubens; Luc Van Gaal; Jérôme Bertherat; Monica Ligueros-Saylan; Andrew Trovato; Gareth Hughes; Luiz R Salgado; Marco Boscaro; Rosario Pivonello
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

10.  Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels.

Authors:  Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn
Journal:  Diabetes Care       Date:  2008-10-28       Impact factor: 19.112
View more
  5 in total

1.  Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.

Authors:  Mattia Barbot; Valentina Guarnotta; Marialuisa Zilio; Filippo Ceccato; Alessandro Ciresi; Andrea Daniele; Giuseppe Pizzolanti; Elena Campello; Anna Chiara Frigo; Carla Giordano; Carla Scaroni
Journal:  Endocrine       Date:  2018-07-06       Impact factor: 3.633

2.  Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.

Authors:  V Guarnotta; G Pizzolanti; A Ciresi; C Giordano
Journal:  J Endocrinol Invest       Date:  2018-02-02       Impact factor: 4.256

3.  Cryptococcal meningitis after transnasal transsphenoidal pituitary microsurgery of ACTH-secreting pituitary adenoma: A case report.

Authors:  Yang Liu; Ming Feng; Yong Yao; Kan Deng; Xinjie Bao; Xiaohai Liu; Renzhi Wang
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

4.  Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study.

Authors:  Luca Manetti; Timo Deutschbein; Jochen Schopohl; Kevin C J Yuen; Michael Roughton; Ulrike Kriemler-Krahn; Libuse Tauchmanova; Ricardo Maamari; Carla Giordano
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 5.  Glucocorticoid excess and COVID-19 disease.

Authors:  Valentina Guarnotta; Rosario Ferrigno; Marianna Martino; Mattia Barbot; Andrea M Isidori; Carla Scaroni; Angelo Ferrante; Giorgio Arnaldi; Rosario Pivonello; Carla Giordano
Journal:  Rev Endocr Metab Disord       Date:  2020-10-06       Impact factor: 6.514
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.